Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Make Your Improvements Last: Begin With the End in Mind.

Pediatrics·2019
Same author

Maintenance of Certification: You Can Make Your Global Health Work Count.

Pediatrics·2019
Same author

First do no harm: overdiagnosis in Pediatrics.

Archivos argentinos de pediatria·2018
Same author

When technology creates uncertainty: pulse oximetry and overdiagnosis of hypoxaemia in bronchiolitis.

BMJ (Clinical research ed.)·2017
Same author

Is It Time for the USPSTF to Inform-But Not Determine-Coverage?

Annals of internal medicine·2016
Same author

The need to build capability and capacity in quality improvement and patient safety.

Pediatrics·2015
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task

Virginia A Moyer,

    Annals of Internal Medicine
    |September 25, 2013
    PubMed
    Summary
    This summary is machine-generated.

    The U.S. Preventive Services Task Force (USPSTF) recommends discussing breast cancer risk-reducing medications like tamoxifen and raloxifene with women over 35 at increased risk. These medications should be offered to those with low risk of adverse effects.

    More Related Videos

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
    08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
    11:38

    Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

    Published on: July 3, 2014

    Related Experiment Videos

    Last Updated: May 7, 2026

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
    10:39

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

    Published on: June 18, 2015

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
    08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
    11:38

    Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

    Published on: July 3, 2014

    Area of Science:

    • Oncology
    • Preventive Medicine
    • Pharmacology

    Background:

    • The U.S. Preventive Services Task Force (USPSTF) previously issued recommendations on breast cancer risk reduction medications in 2002.
    • Selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene are key pharmacologic agents for breast cancer risk reduction.

    Purpose of the Study:

    • To update the 2002 USPSTF recommendation regarding the use of medications for breast cancer risk reduction.
    • To evaluate the effectiveness, adverse effects, and subgroup variations of tamoxifen and raloxifene for breast cancer risk reduction.

    Main Methods:

    • Systematic review of evidence on the efficacy and safety of breast cancer risk-reducing medications.
    • Analysis of meta-analyses of placebo-controlled trials comparing tamoxifen and raloxifene.
    • Focus on asymptomatic women aged 35 years or older without a history of breast cancer or related conditions.

    Main Results:

    • Tamoxifen and raloxifene demonstrate effectiveness in reducing breast cancer risk.
    • Potential adverse effects and variations in response across different patient subgroups were considered.
    • The balance of benefits and harms was assessed through meta-analysis of placebo-controlled trials.

    Conclusions:

    • Clinicians should engage in shared decision-making with women at increased risk for breast cancer regarding risk-reducing medications.
    • Offer tamoxifen or raloxifene to women at increased breast cancer risk and low risk for adverse effects (B recommendation).
    • Do not routinely use these medications for primary breast cancer risk reduction in women not at increased risk (D recommendation).